S. 4867 · 116th Congress
Accelerating Access to Critical Therapies for ALS Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
CoonsSponsor15 cosponsors · 7 D, 7 R, 1 I
R
Murkowski
JB
R
Boozman
JS
D
Shaheen
SC
R
Capito
AK
I
King
KG
D
Gillibrand
KL
R
Loeffler
KC
R
Cramer
DF
D
Feinstein
JH
R
Hoeven
DJ
D
Jones
PL
D
Leahy
JM
D
Manchin
JM
R
Moran
KS
D
Sinema1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.
What it does: CRS summary · Introduced in Senate · Oct 26, 2020
Accelerating Access to Critical Therapies for ALS Act
This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.
The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.
HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Accelerating Access to Critical Therapies for ALS Act
Latest action (Oct 26, 2020): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Oct 26, 2020
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.